John Paulson’s Alnylam Pharmaceuticals ALNY Stock Holding History

John Paulson’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-19,300	Closed	-$723K	–	98
2016 Q4	$723K	Hold	19,300	–	–	0.01%	94
2016 Q3	$1.31M	Hold	19,300	–	–	0.01%	89
2016 Q2	$1.07M	Buy	19,300 +7,000	+57%	+$441K	0.01%	78
2016 Q1	$772K	Hold	12,300	–	–	0.01%	90
2015 Q4	$1.16M	Buy	+12,300	New	+$1.14M	0.01%	71

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

John Paulson's ALNY Position: Q1 2017 in Review

John Paulson sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2017, closing a stake of 19,300 shares — an estimated $723K sold.

John Paulson first reported a position in ALNY in Q4 2015 and held it in 5 quarters. The position peaked at $1.31M in Q3 2016. 199 funds tracked by Wall St. Rank hold ALNY as of Q1 2017.

John Paulson reported no remaining Alnylam Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
John Paulson sold 19,300 Alnylam Pharmaceuticals shares in Q1 2017, an estimated $723K.
John Paulson first reported a position in Alnylam Pharmaceuticals in Q4 2015 and held it in 5 quarters.
John Paulson's Alnylam Pharmaceuticals position peaked at $1.31M in Q3 2016.
199 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2017.

Based on Paulson & Co's 13F filing for Q1 2017, filed 15 May 2017.